CoChat
Sign Up
Cited by 47Diabetes and associated disordersT-cell and B-cell ImmunologyDiabetes Management and Research

Immune intervention in type 1 diabetes

Open access
Michels, Aaron W., Eisenbarth, George S.·2011·Seminars in Immunology
DOI 10.1016/j.smim.2011.07.003PMC PMC3177994
Open this paper in CoChat — free account

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.smim.2011.07.003

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In patients with type 1 diabetes with surviving β cells, insulitic lesions are usually lobular, analogous to the lobular loss of melanocytes in vitiligo.

    “In patients with type 1 diabetes with surviving β cells, insulitic lesions are usually lobular, analogous to the lobular loss of melanocytes in vitiligo.60”

    From Type 1 diabetes (2014) · cites this paper as [60]

    The Introduction (page unavailable) describes lobular β-cell destruction in patients with residual β cells, with normal-appearing islets beside areas lacking β cells. It does not describe insulitic lesions as usually lobular; it says insulitis is minimal in the great majority of pancreases examined at or after onset. Our copy also does not make the comparison with melanocyte loss in vitiligo. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 66

  1. [1]Eisenbarth GS Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes Diabetes 2010 59 4 759 774 20350969 PMC2844823
  2. [2]Bluestone JA Herold K Eisenbarth G Genetics, pathogenesis and clinical interventions in type 1 diabetes Nature 2010 464 7293 1293 1300 20432533 PMC4959889
  3. [3]Maahs DM Rewers M Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done J Clin Endocrinol Metab 2006 91 10 3757 3759 17028289
  4. [5]Harjutsalo V Sjoberg L Tuomilehto J Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study Lancet 2008 371 9626 1777 1782 18502302
  5. [6]Patterson CC Dahlquist GG Gyurus E Green A Soltesz G Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study Lancet 2009 373 9680 2027 2033 19481249
  6. [7]Eisenbarth GS Type I diabetes mellitus. A chronic autoimmune disease N Engl J Med 1986 314 1360 1368 3517648
  7. [8]Srikanta S Ganda OP Gleason RE Jackson RA Soeldner JS Eisenbarth GS Pre-type I diabetes. Linear loss of beta cell response to intravenous glucose Diabetes 1984 33 8 717 720 6378696
  8. [9]Sosenko JM Krischer JP Palmer JP Mahon J Cowie C Greenbaum CJ A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1 Diabetes Care 2008 31 3 528 533 18000175
  9. [11]Wenzlau JM Juhl K Yu L Moua O Sarkar SA Gottlieb P The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes Proc Natl Acad Sci U S A 2007 104 43 17040 17045 17942684 PMC2040407
  10. [12]Sherr J Sosenko J Skyler JS Herold KC Prevention of type 1 diabetes: the time has come Nat Clin Pract Endocrinol Metab 2008 18446141
  11. [13]Achenbach P Bonifacio E Ziegler AG Predicting type 1 diabetes Curr Diab Rep 2005 5 2 98 103 15794911
  12. [14]Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT) The DCCT Research Group J Clin Endocrinol Metab 1987 65 1 30 36 2884229
  13. [15]Grajwer LA Pildes RS Horwitz DL Rubenstein AH Control of juvenile diabetes mellitus and its relationship to endogenous insulin secretion as measured by C-peptide immunoreactivity J Pediatr 1977 90 1 42 48 830892
  14. [16]Madsbad S Faber OK Binder C McNair P Christiansen C Transbol I Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes Diabetes 1978 27 Suppl. 1 262 264 344117
  15. [17]O’Meara NM Sturis J Herold KC Ostrega DM Polonsky KS Alterations in the patterns of insulin secretion before and after diagnosis of IDDM Diabetes Care 1995 18 4 568 571 7497873
  16. [18]Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial The Diabetes Control and Complications Trial Research Group Ann Intern Med 1998 128 7 517 523 9518395
  17. [19]The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus New Engl J Med 1993 329 977 986 8366922
  18. [20]Keenan HA Sun JK Levine J Doria A Aiello LP Eisenbarth G Residual insulin production and pancreatic ss-cell turnover after 50 years of diabetes: Joslin Medalist Study Diabetes 2010 59 11 2846 2853 20699420 PMC2963543
  19. [22]Gianani R Campbell-Thompson M Sarkar SA Wasserfall C Pugliese A Solis JM Dimorphic histopathology of long-standing childhood-onset diabetes Diabetologia 2010 20062967
  20. [24]Harris PE Ferrara C Barba P Polito T Freeby M Maffei A VMAT2 gene expression and function as it applies to imaging beta-cell mass J Mol Med 2008 86 1 5 16 17665159
  21. [25]Medarova Z Tsai S Evgenov N Santamaria P Moore A In vivo imaging of a diabetogenic CD8+ T cell response during type 1 diabetes progression Magn Reson Med 2008 59 4 712 720 18302224
  22. [28]Stiller CR Dupre J Gent M Jenner MR Keown PA Laupacis A Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset Science 1984 223 4643 1362 1367 6367043
  23. [29]Bougneres PF Carel JC Castano L Boitard C Gardin JP Landais P Factors associated with early remission of type I diabetes in children treated with cyclosporine N Engl J Med 1988 318 11 663 670 3125434
  24. [30]Eisenbarth GS Srikanta S Jackson R Rabinowe S Dolinar R Aoki T Anti-thymocyte globulin and prednisone immunotherapy of recent onset type I diabetes mellitus Diabetes Res 1985 2 6 271 276 3878262
  25. [31]Chatenoud L Thervet E Primo J Bach JF Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice Proc Natl Acad Sci USA 1994 91 1 123 127 8278351 PMC42898
  26. [32]Chatenoud L Bach JF Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse Int Rev Immunol 2005 24 3-4 247 267 16036377
  27. [33]Herold KC Hagopian W Auger JA Poumian-Ruiz E Taylor L Donaldson D Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 2002 346 22 1692 1698 12037148
  28. [34]Herold KC Gitelman SE Masharani U Hagopian W Bisikirska B Donaldson D A Single Course of Anti-CD3 Monoclonal Antibody hOKT3{gamma}1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes Diabetes 2005 54 6 1763 1769 15919798 PMC5315015
  29. [35]Herold KC Gitelman S Greenbaum C Puck J Hagopian W Gottlieb P Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin Immunol 2009 132 2 166 173 19443276 PMC2735402
  30. [36]Keymeulen B Vandemeulebroucke E Ziegler AG Mathieu C Kaufman L Hale G Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes N Engl J Med 2005 352 25 2598 2608 15972866
  31. [37]Keymeulen B Walter M Mathieu C Kaufman L Gorus F Hilbrands R Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass Diabetologia 2010 20225393
  32. [38]Keymeulen B Candon S Fafi-Kremer S Ziegler A Leruez-Ville M Mathieu C Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients Blood 2010 115 6 1145 1155 20007541
  33. [39]Belghith M Bluestone JA Barriot S Megret J Bach JF Chatenoud L TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes Nat Med 2003 9 9 1202 1208 12937416
  34. [40]Chatenoud L CD3 antibody treatment stimulates the functional capability of regulatory T cells Novartis Found Symp 2003 252 279 286 14609225
  35. [41]Herold KC Burton JB Francois F Poumian-Ruiz E Glandt M Bluestone JA Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala) J Clin Invest 2003 111 3 409 418 12569167 PMC151852
  36. [42]Chatenoud L Bluestone JA CD3-specific antibodies: a portal to the treatment of autoimmunity Nat Rev Immunol 2007 7 8 622 632 17641665
  37. [43]Bisikirska B Colgan J Luban J Bluestone JA Herold KC TCR stimulation with modified anti-CD3 mAb expands CD8 T cell population and induces CD8CD25 Tregs J Clin Invest 2005 115 10 2904 2913 16167085 PMC1201661
  38. [44]Skyler JS Greenbaum CJ Lachin JM Leschek E Rafkin-Mervis L Savage P Type 1 Diabetes TrialNet--an international collaborative clinical trials network Ann N Y Acad Sci 2008 1150 14 24 19120262 PMC2918900
  39. [45]Willcox A Richardson SJ Bone AJ Foulis AK Morgan NG Analysis of islet inflammation in human type 1 diabetes Clin Exp Immunol 2009 155 2 173 181 19128359 PMC2675247
  40. [47]Lee RS Rusche JR Maloney ME Sachs DH Sayegh MH Madsen JC CTLA4Ig-induced linked regulation of allogeneic T cell responses J Immunol 2001 166 3 1572 1582 11160198
  41. [48]Barlow AK Like AA Anti-CD2 monoclonal antibodies prevent spontaneous and adoptive transfer of diabetes in the BB/Wor rat Am J Pathol 1992 141 5 1043 1051 1359788 PMC1886660
  42. [49]Gabay C Lamacchia C Palmer G IL-1 pathways in inflammation and human diseases Nat Rev Rheumatol 2010 6 4 232 241 20177398
  43. [50]Larsen CM Faulenbach M Vaag A Volund A Ehses JA Seifert B Interleukin-1-receptor antagonist in type 2 diabetes mellitus N Engl J Med 2007 356 15 1517 1526 17429083
  44. [51]Larsen CM Faulenbach M Vaag A Ehses JA Donath MY Mandrup-Poulsen T Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes Diabetes Care 2009 32 9 1663 1668 19542207 PMC2732140
  45. [52]Koulmanda M Bhasin M Hoffman L Fan Z Qipo A Shi H Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice Proc Natl Acad Sci U S A 2008 105 42 16242 16247 18852471 PMC2570971
  46. [53]Louvet C Szot GL Lang J Lee MR Martinier N Bollag G Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proc Natl Acad Sci U S A 2008 PMC2596241 19015530
  47. [54]Nussbaum G Zanin-Zhorov A Quintana F Lider O Cohen IR Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis Int Immunol 2006 16893923
  48. [55]Couri CE Oliveira MC Stracieri AB Moraes DA Pieroni F Barros GM C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus JAMA 2009 301 15 1573 1579 19366777
  49. [56]Weiner HL Oral tolerance, an active immunologic process mediated by multiple mechanisms J Clin Invest 2000 106 8 935 937 11032852 PMC314352
  50. [58]Hjorth M Axelsson S Ryden A Faresjo M Ludvigsson J Casas R GAD-alum treatment induces GAD(65)-specific CD4(+)CD25(high)FOXP3(+) cells in type 1 diabetic patients Clin Immunol 2010 21044870
  51. [59]Mahon JL Sosenko JM Rafkin-Mervis L Krause-Steinrauf H Lachin JM Thompson C The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results Pediatr Diabetes 2009 10 2 97 104 18823409
  52. [62]Walter M Philotheou A Bonnici F Ziegler AG Jimenez R No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes Diabetes Care 2009 32 11 2036 2040 19690081 PMC2768201
  53. [63]Thrower SL James L Hall W Green KM Arif S Allen JS Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study Clin Exp Immunol 2009 155 2 156 165 19040615 PMC2675245
  54. [64]Skyler JS Update on worldwide efforts to prevent type 1 diabetes Ann N Y Acad Sci 2008 1150 190 196 19120293 PMC2928677
  55. [65]Nakayama M Abiru N Moriyama H Babaya N Liu E Miao D Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice Nature 2005 435 7039 220 223 15889095 PMC1364531
  56. [66]Concannon P Rich SS Nepom GT Genetics of type 1A diabetes N Engl J Med 2009 360 16 1646 1654 19369670
  57. [68]Wicklow BA Polychronakos C Insulin auto-immunity: implications for the prevention of Type 1 diabetes mellitus Expert Rev Clin Immunol 2009 5 1 55 62 20476900
  58. [69]Barratt BJ Payne F Lowe CE Hermann R Healy BC Harold D Remapping the Insulin Gene/IDDM2 Locus in Type 1 Diabetes Diabetes 2004 53 7 1884 1889 15220214
  59. [73]Visser JT Lammers K Hoogendijk A Boer MW Brugman S Beijer-Liefers S Restoration of impaired intestinal barrier function by the hydrolysed casein diet contributes to the prevention of type 1 diabetes in the diabetes-prone BioBreeding rat Diabetologia 2010 53 12 2621 2628 20853098 PMC2974912
  60. [74]Matthews JB Staeva TP Bernstein PL Peakman M von HM Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group Clin Exp Immunol 2010 160 2 176 184 20629979 PMC2857940
  61. [75]Michels AW Nakayama M 2The anti-insulin trimolecular complex in type 1 diabetes Curr Opin Endocrinol Diabetes Obes 2010 PMC4012426 20489610
  62. [77]Steenkiste A Valdes AM Feolo M Hoffman D Concannon P Noble J 14th International HLA and Immunogenetics Workshop: report on the HLA component of type 1 diabetes Tissue Antigens 2007 69 Suppl 1 214 225 17445204
  63. [78]Palmer JP Asplin CM Clemons P Lyen K Tatpati O Raghu PK Insulin antibodies in insulin-dependent diabetics before insulin treatment Science 1983 222 4630 1337 1339 6362005
  64. [79]Achenbach P Koczwara K Knopff A Naserke H Ziegler AG Bonifacio E Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes J Clin Invest 2004 114 4 589 597 15314696 PMC503771
  65. [80]Lee KH Wucherpfennig KW Wiley DC Structure of a human insulin peptide/HLA-DQ8 complex and susceptibility to type 1 diabetes Nature Immunology 2001 2 501 507 11376336
  66. [81]Stadinski BD Zhang L Crawford F Marrack P Eisenbarth GS Kappler JW Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register Proc Natl Acad Sci U S A 2010 107 24 10978 10983 20534455 PMC2890771

Cited by

Sorted by citations

Authors
Michels, A. W., & Eisenbarth, G. S.
Affiliations
University of Colorado Denver (US)
ORCID
Michels, Aaron W.
Venue
Seminars in Immunology
Publisher
Elsevier BV
Published
2011-06
Volume
23
Issue
3
Pages
214-219
ISSN
1044-5323 (ISSN-L)
DOI
10.1016/j.smim.2011.07.003
PMC
PMC3177994
OpenAlex
W2074214836
Cited by
47
References
14
Citations by year
2025: 2 · 2024: 1 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 6 · 2014: 5 · 2013: 9 · 2012: 12
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Seminars in Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute of Allergy and Infectious Diseases (U519 AI050864-08, U19AI050864)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057516, R01DK055969, K08DK095995)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 1 diabetes, immunotherapy, beta cell destruction, autoimmune disease, immune tolerance, antigen-specific immunotherapy, immunosuppression, environmental therapy, TrialNet
MeSH terms
Animals, Antigens, Diabetes Mellitus, Type 1, Dietary Proteins, Humans, Immune Tolerance, Immunosuppression Therapy, Autoimmunity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review